S. 1695: Biologics Price Competition and Innovation Act of 2007

110th Congress · introduced 2007-06-26 · Health · Latest: Placed on Senate Legislative Calendar under General Orders. Calendar No. 1127.

federal

Follow this bill, step by step

Where it came from: introduced 2007-06-26 · official record
Who proposed it: Sen. Kennedy, Edward M. [D-MA] · what a sponsor is
What happened next: no floor votes in our records yet. Why?
Where it stands now: Placed on Senate Legislative Calendar under General Orders. Calendar No. 1127. Not final yet: this can still change. We check for updates every day.
If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.

What does this mean?

Official title

Biologics Price Competition and Innovation Act of 2007

Plain summary

Biologics Price Competition and Innovation Act of 2007 - Amends the Public Health Service Act to allow a person to submit an application for licensure of a biological product based on its similarity to a licensed biological product (the reference product). Sets forth application requirements, including that the application demonstrate that: (1) the biological is biosimilar to a reference product based upon data derived from studies; (2) the biological product and reference product utilize the same mechanism of action; and (3) the route of administration, the dosage form, and the strength of the biological product are the same as those of the reference product. Allows an application to include information demonstrating that the biological product is interchangeable with the reference product. Requires the Secretary of Health and Human Services to license the biological product if the information submitted in the application is sufficient to show that the biological product is biosimilar to or interchangeable with the reference product. Allows products to be determined to be interchangeable if: (1) the biological product is biosimilar to the reference product and can be expected to produce the same clinical result as the reference product in any given patient; and (2) the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch. Prohibits a biological product from being evaluated against more than one reference product. Prohibits the Secretary from determining that a second or subsequent biological product is interchangeable with a reference product for any condition of use for specified periods based on the marketing of, and the presence or status of litigation involving, the first biosimilar biological product deemed interchangeable with the same reference product. Prohibits approval of an application under this Act from being made effective until 12 years after the reference product was first licensed. Authorizes the Secretary to issue guidance with respect to the licensure of a biological product after public comment. Requires the Secretary to establish a process through which the public may provide the Secretary with input regarding priorities for issuing guidance. Sets forth requirements for any product class-specific guidance that may be issued by the Secretary, including that such guidance include a description of the criteria that the Secretary will use to determine whether a biological product is highly similar to or interchangeable with a reference product in such product class. Allows the Secretary to indicate in a guidance document that the science and experience with respect to a product or product class does not allow approval of an application for a license under this Act. Sets forth provisions governing the exchange of confidential information related to patents for biological products. Requires confidential information to be used for the sole and exclusive purpose of determining whether a claim of patent infringement could reasonably be brought against the biosimilar biological product. Deems a disclosure of any confidential information in violation of this Act to cause the applicant to suffer irreparable harm for which there is no adequate legal remedy. Requires good faith negotiations between the reference product sponsor and an applicant under this Act. Sets forth provisions regarding patent infringement lawsuits, including the time frame for a reference product sponsor to bring an action for patent infringement. Requires the Secretary to: (1) develop recommendations with respect to the goals for the review process of biosimilar biological product applications; (2) collect and evaluate data regarding the cost of reviewing such applications; and (3) determine whether to alter the user fee applicable to such applications. Establishes the Biological Product Savings Fund in the Treasury to be funded with savings to the federal government as a result of the enactment of this Act and to be expended on activities authorized under the Public Health Service Act. Directs the Comptroller General to study and report to Congress on: (1) the extent to which pediatric studies of biological products are required under the Federal Food, Drug, and Cosmetic Act; and (2) any pediatric needs not being met under existing authority. Extends the time frame for a sponsor to have market exclusivity for a biological product designated for a rare disease or condition.

Congressional Research Service summary (Reported to Senate with amendment(s)), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

If it passes both chambers and is signed, it becomes law.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

Biologics Price Competition and Innovation Act of 2007

Source: Congressional Research Service summary (Reported to Senate with amendment(s))

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Sen. Kennedy, Edward M. [D-MA] · 4 cosponsors

Cost estimate: CBO cost estimate: S. 1695, Biologics Price Competition and Innovation Act of 2007 (2008-06-25); CBO cost estimate: S. 1695, Biologics Price Competition and Innovation Act of 2007 (2008-06-25)

Cosponsors on this site

Charles E. Schumer (D-NY)

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Words on this page, explained (2)

Authorization: A law that creates or continues a government program and says what it may do, often with a suggested spending ceiling. An authorization alone does not provide money; a separate appropriation does.
Public comment: A chance for anyone to tell a government agency what they think about a proposed rule or plan before it is final. Agencies must consider the comments they receive.

Plain meanings written from linked sources. All words.

Sources

Congressional Research Service summary (Reported to Senate with amendment(s))
Congress.gov
Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-110s1695.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/110/s>

Record fed-us-cong110-s1695 · catalog fed-us-congress-bills-cong110 · updated 2026-11-15 by psicol fed-bills-cong110